Navigation Links
Undisclosed in Medical News

Dissident Stockholder Ted Karkus Found to Have Undisclosed Financial Arrangements With Dr. Richard A. Rosenbloom, COO Of Quigley Pharma, From 2008 to Date of Proxy: Rosenbloom Suspended Without Pay Pending Further Investigation

DOYLESTOWN, Pa., May 19 /PRNewswire-FirstCall/ -- The Quigley Corporation, (Nasdaq: QGLY ) , www.quigleyco.com , today announced that it has uncovered an improper financial relationship between Ted Karkus and the Company's Quigley Pharma, Inc. wholly-owned subsidiary COO, Dr. Richard A. ...

Coffee king American Flavor 3 in 1 Coffee mix contains undisclosed milk protein

Ottawa - The Canadian Food Inspection Agency (CFIA) has issued a warning for those who are allergic to milk, to avoid consumption of the Coffee king American Flavor// 3 in 1 Coffee mix brand. This product is said to contain a milk protein ingredient which the manufacturers have not disclosed on the...

Allergy Alarm: Sam's Choice Milk Chocolate Turns Bitter with Undisclosed 'Nuts'

Brach's Confections, Inc. of Dallas, Texas are tough nuts to crack, indeed. Presently, they have withdrawn a batch of production of Sam's Choice Belgian Milk Chocolate Bars,// due to the presence of undeclared almonds. This is a precautionary measure to ensure safety for all those who are allergic ...

Micromet, Inc. Reports Second Quarter 2009 Financial Results

...eement with Bayer Schering Pharma AG under which Bayer Schering Pharma was granted an exclusive option to license a specified BiTE antibody against an undisclosed solid tumor target. Other BiTE antibodies targeting MSCP, CD33, HER2, EGFR and other targets are in various stages of preclinical development. ...

Ned Russell Joins Saatchi & Saatchi Wellness

...nth SSW was awarded the Durex account following a review. In addition, the agency has picked up four additional assignments in health and wellness for undisclosed new products. "Saatchi & Saatchi Wellness is an agency with a distinct point of view and focus - marketing well-being is a strong differ...

Forest Laboratories and H. Lundbeck A/S Enter Into Settlement Agreement With Sun and Caraco Related to LEXAPRO(R) Patent Litigation

...xclusivity. Caraco will take over the commercialization and sale of several products from Forest's Inwood business. Caraco will pay Forest an undisclosed advance against royalties and royalties on net sales of these products. In exchange for an upfront payment (and royalties but only if the tech...

Health Club Media Network Acquires the Alloy Fitness Network

...ational brands in health clubs, announced today its acquisition of the Alloy Fitness Network from Alloy Media + Marketing. The transaction includes an undisclosed cash sum plus certain future contingent payments. The Alloy Fitness Network includes contractual agreements for media panel placements in over 70...

Catalyst Biosciences Announces Agreement With MedImmune to Discover and Develop Engineered Protease Therapeutics

...ll address inflammatory and autoimmune diseases. Catalyst will receive undisclosed upfront licensing fees, full-time employee (FTE) support and milestone paym...preclinical development by Catalyst of Alterase(TM) therapeutics against an undisclosed target, with an option to expand the agreement to include a second target. ...

Crestor Patent Invalidity Evidence Uncovered By Article One Partners Community

...mmunity working to legitimize the validity of patents. Community members - whom Article One calls Advisors - have an opportunity to send in previously undisclosed evidence of patent validity. By tapping the unique knowledge and referral networks of our Advisors, this evidence known as prior art can be discovered...

KV Pharmaceutical Forms Licensing Partnership with Gedeon Richter

...and distribute certain of KV's proprietary technologies and products in its territories, including the European Union. KV Pharmaceutical will receive undisclosed milestones and royalties for products developed under the terms of the agreement. The agreement also provides for the development of additional p...
Undisclosed in Medical Technology

EUCODIS Bioscience Achieves Development Milestone in Second Collaboration With Lohmann Animal Health

...d marketing enzymes and other proteins for the chemical industry, announced today that it has achieved an important milestone in the development of an undisclosed protein for Lohmann Animal Health (LAH), a leading provider of feed components and vaccines for farm animals. This achievement triggered a milestone p...

Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients

...eement with Bayer Schering Pharma AG under which Bayer Schering Pharma was granted an exclusive option to license a specified BiTE antibody against an undisclosed solid tumor target. Micromet's preclinical product pipeline includes several novel BiTE antibodies generated with its proprietary BiTE antibody plat...

Micromet Presents Update on Blinatumomab's Response Rate and Duration in a Phase 1 Study in Non-Hodgkin's Lymphoma Patients

...eement with Bayer Schering Pharma AG under which Bayer Schering Pharma was granted an exclusive option to license a specified BiTE antibody against an undisclosed solid tumor target. Micromet's preclinical product pipeline includes several novel BiTE antibodies generated with its proprietary BiTE antibody plat...

Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies

...body and will thereafter assume responsibility for further clinical development and commercialisation on a worldwide basis. OBT will receive an undisclosed upfront payment and will be eligible for up to a total of $370m (GBP244m) upon the achievement of specified discovery, development, regulatory and com...

Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day

...rthritis, psoriasis, or multiple sclerosis. Micromet has granted an exclusive option to Bayer Schering Pharma AG to license a BiTE antibody against an undisclosed solid tumor target. Additional BiTE antibodies, targeting CEA, CD33, Her2, EGFR and MCSP, respectively, are in different stages of preclinical develop...

Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer Cells

...rthritis, psoriasis, or multiple sclerosis. Micromet has granted an exclusive option to Bayer Schering Pharma AG to license a BiTE antibody against an undisclosed solid tumor target. Additional BiTE antibodies, targeting CEA, CD33, Her2, EGFR and MCSP, respectively, are in different stages of preclinical develop...

Micromet Receives Milestone Payment for Filing of the First Clinical Trial Application for MT203

... to be initiated in the first half of 2009. Micromet has granted an exclusive option to Bayer Schering Pharma AG to license a BiTE antibody against an undisclosed solid tumor target. Additional BiTE antibodies, targeting CEA, CD33, Her2, EGFR and MCSP, respectively, are in different stages of preclinical develop...

Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients

...rthritis, psoriasis, or multiple sclerosis. Micromet has granted an exclusive option to Bayer Schering Pharma AG to license a BiTE antibody against an undisclosed solid tumor target. Additional BiTE antibodies, targeting CEA, CD33, Her2, EGFR and MCSP, respectively, are in different stages of preclinical develop...

TissueGene Announces Regulatory Allowance to Initiate Phase IIa Study of TG-C in South Korea for Osteoarthritis of the Knee

...dates TG-C and TG-B, developed for the regeneration of cartilage and bone, respectively. Under the terms of the agreement, TissueGene has received an undisclosed up-front payment and will receive on-going royalty payments based upon future sales. TissueGene is currently completing Phase I clinical trials in th...

Ambrx and Merck Serono Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance

...payment to Ambrx, and Ambrx is eligible to receive undisclosed clinical, regulatory and commercial milestone paym...ucts resulting from this collaboration, as well as undisclosed royalties on the associated worldwide net sales. A... as profit. In addition, Merck Serono will make an undisclosed equity investment in Ambrx. Additional terms of t...
Undisclosed in Biological News

Chantix side effects no worse with depression history

...e trial detected only one serious psychiatric event involving suicidal thoughts and requiring hospitalization. It was in a person who had a previously undisclosed history of bipolar disorder. ...

Re-analysis of cigarettes confirms tobacco companies increased addictive nicotine 11 percent

... smoking each year. In conclusion, according to the HSPH researchers, the extended analysis of MDPH data has demonstrated its potential to reveal undisclosed hazards to human health. They suggest that MDPH amend its unique reporting requirements to include more information about cigarette and smokeless toba...
Undisclosed in Biological Technology

Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway

LAUSANNE, Switzerland and BANGALORE, India, November 20 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Aurigene Discovery Technologies Ltd (Aurigene), a Bangalore-based fully...

Micromet Closes $80.5 Million Public Offering of Common Stock

...chering Pharma AG under which Bayer Schering Pharma was granted an exclusive option until January 2010 to license a specified BiTE antibody against an undisclosed solid tumor target. Other BiTE antibodies targeting MSCP, CD33, HER2, EGFR and other targets are in various stages of preclinical development. ...

Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab

...eement with Bayer Schering Pharma AG under which Bayer Schering Pharma was granted an exclusive option to license a specified BiTE antibody against an undisclosed solid tumor target. Other BiTE antibodies targeting MSCP, CD33, HER2, EGFR and other targets are in various stages of preclinical development. ...

Micromet Announces Pricing of Public Offering of Common Stock

...chering Pharma AG under which Bayer Schering Pharma was granted an exclusive option until January 2010 to license a specified BiTE antibody against an undisclosed solid tumor target. Other BiTE antibodies targeting MSCP, CD33, HER2, EGFR and other targets are in various stages of preclinical development. ...

Micromet Announces Public Offering of Common Stock

...chering Pharma AG under which Bayer Schering Pharma was granted an exclusive option until January 2010 to license a specified BiTE antibody against an undisclosed solid tumor target. Other BiTE antibodies targeting MSCP, CD33, HER2, EGFR and other targets are in various stages of preclinical development. ...

Micromet, Inc. to Host Conference Call and Webcast to Report Second Quarter 2009 Financial Results on August 6, 2009

...eement with Bayer Schering Pharma AG under which Bayer Schering Pharma was granted an exclusive option to license a specified BiTE antibody against an undisclosed solid tumor target. Other BiTE antibodies targeting MSCP, CD33, HER2, EGFR and other targets are in various stages of preclinical development. ...

BioWa Announces License of POTELLIGENT(R) Technology to Merck KGaA

...nts Merck KGaA non-exclusive rights to research, develop and commercialize therapeutic antibodies generated through POTELLIGENT((R)) Technology for an undisclosed number of targets. In return, BioWa will receive upfront payments, and may receive development milestone payments and royalties on products. Other d...

Micromet Added to Russell 3000 Index

...eement with Bayer Schering Pharma AG under which Bayer Schering Pharma was granted an exclusive option to license a specified BiTE antibody against an undisclosed solid tumor target. Other BiTE antibodies targeting MSCP, CD33, HER2, EGFR and other targets are in various stages of preclinical development. F...

AFFiRiS AG: 1st Place in Venture Capital & Private Equity Awards for MIG Fonds and AFFiRiS

...seases that have so far seemed unsuitable for treatment by vaccination, but that represent markets worth billions. Vaccine candidates for four further undisclosed chronic diseases are currently being developed by AFFiRiS AG. Asked about the success story of AFFiRiS AG and the current award, Andreas Höfle...

Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009

...eement with Bayer Schering Pharma AG under which Bayer Schering Pharma was granted an exclusive option to license a specified BiTE antibody against an undisclosed solid tumor target. Micromet's preclinical product pipeline includes several novel BiTE antibodies generated with its proprietary BiTE antibody plat...
Other Tags
(Date:5/24/2015)... May 24, 2015 Scientists with Cardno ... on air quality compliance issues that may have raised ... Surviving Mesothelioma has just posted an article on the ... , The group found airborne asbestos levels well above ... between 1984 and 2011. , “Asbestos compliance sampling data ...
(Date:5/24/2015)... Indiana Fiber Network, LLC (IFN), the leading ... America, Inc. (MTA) has selected IFN as a fiber ... Enterprise Sales Manager, fiber route diversity and network redundancy ... provides MTA with the diverse fiber transport from their ... and voice carriers located at Henry Street in Indianapolis, ...
(Date:5/23/2015)... On Saturday, May 23, 2015, over 100 volunteers ... Florida City exactly five years to the day after the ... A large fire tore through the Branches United Methodist Church ... the middle of the night as neighbors, staff and Branches' ... even though it is suspected that the fire began accidentally. ...
(Date:5/23/2015)... May 23, 2015 On Wednesday, May ... “the company has been the target of a sophisticated ... of the company’s ongoing Information Technology (IT) security efforts ... , The most notable attack on health insurers ... Inc., the nation’s second largest health insurer, revealed that ...
(Date:5/23/2015)... WI (PRWEB) May 23, 2015 ... Acceleration at the Sports Medicine and Rehabilitation Center, 557 ... clinic program, Mondays, June 1-July 20, 5:30-6:30 pm. , ... USAT coach, and Laurie Finke, RN, BSN, who will ... exercises, education on nutrition, running mechanics and show selection ...
Breaking Medicine News(10 mins):Health News:New Analysis Finds Too Many Employers Ignored OSHA Asbestos Guidelines, According to Surviving Mesothelioma 2Health News:Indiana Fiber Network, LLC Enables Midwest Telecom of America with Fiber Route Diversity 2Health News:Five Years After Fire, Branches Rebuilds Playground 2Health News:One Headline Making Cyber Attack Sparks Discovery of Another 2Health News:One Headline Making Cyber Attack Sparks Discovery of Another 3Health News:One Headline Making Cyber Attack Sparks Discovery of Another 4
(Date:5/14/2015)... 14, 2015  Verificient Technologies, Inc., a ... online remote proctoring, announced a new alliance ... and creator of the Canvas Learning Management ... companies will benefit from the seamless integration ... As a fully integrated multifactor biometrics behavioral ...
(Date:5/10/2015)... -- Fingerprint Cards (FPC) has received an order ... distributor World Peace Industrial Group (WPI), part of WPG Holdings. ... . Deliveries are planned to take place during Q3 ... in China . The order value of ... + 1 000 MSEK for 2015.   Jörgen Lantto, ...
(Date:5/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, reminds investors and media that  Mr. David Tunnell ... SECURE CONNEXIONS AMERICA 2015, held in Washington DC ... conference is organized into a series of nine session tracks. ... Fraud: Where is the Trust in Cyberspace? and will ...
Breaking Biology News(10 mins):Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
Other Contents